These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31607342)

  • 1. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.
    Puente J; Gascon F; Ponte B; de la Fuente D
    Artif Intell Med; 2019 Sep; 100():101703. PubMed ID: 31607342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On macroeconomic characteristics of pharmaceutical generics and the potential for manufacturing and consumption under fuzzy conditions.
    Gascón F; de la Fuente D; Puente J; Lozano J
    Artif Intell Med; 2007 Nov; 41(3):223-35. PubMed ID: 17719212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
    Gascón F; Lozano J; Ponte B; de la Fuente D
    Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
    Schuhmacher A; Gassmann O; McCracken N; Hinder M
    J Transl Med; 2018 May; 16(1):119. PubMed ID: 29739427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hybrid mathematical programming model for optimal project portfolio selection using fuzzy inference system and analytic hierarchy process.
    Tavana M; Khosrojerdi G; Mina H; Rahman A
    Eval Program Plann; 2019 Dec; 77():101703. PubMed ID: 31442587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 8. Towards a Fuzzy Bayesian Network Based Approach for Safety Risk Analysis of Tunnel-Induced Pipeline Damage.
    Zhang L; Wu X; Qin Y; Skibniewski MJ; Liu W
    Risk Anal; 2016 Feb; 36(2):278-301. PubMed ID: 26224125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fuzzy Logic in neurosurgery: predicting poor outcomes after lumbar disk surgery in 501 consecutive patients.
    Shamim MS; Enam SA; Qidwai U
    Surg Neurol; 2009 Dec; 72(6):565-72; discussion 572. PubMed ID: 20082825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
    Jekunen A
    Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target small firms for antibiotic innovation.
    Hwang TJ; Carpenter D; Kesselheim AS
    Science; 2014 May; 344(6187):967-9. PubMed ID: 24876477
    [No Abstract]   [Full Text] [Related]  

  • 12. Uncertainty modeling of improved fuzzy functions with evolutionary systems.
    Celikyilmaz A; Turksen IB
    IEEE Trans Syst Man Cybern B Cybern; 2008 Aug; 38(4):1098-110. PubMed ID: 18632400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated breast cancer risk assessment and management model based on fuzzy cognitive maps.
    Subramanian J; Karmegam A; Papageorgiou E; Papandrianos N; Vasukie A
    Comput Methods Programs Biomed; 2015 Mar; 118(3):280-97. PubMed ID: 25697987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional technology gap and innovation efficiency trap in Chinese pharmaceutical manufacturing industry.
    Lai H; Shi H; Zhou Y
    PLoS One; 2020; 15(5):e0233093. PubMed ID: 32433705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fuzzy decision support systems to diagnose musculoskeletal disorders: A systematic literature review.
    Farzandipour M; Nabovati E; Saeedi S; Fakharian E
    Comput Methods Programs Biomed; 2018 Sep; 163():101-109. PubMed ID: 30119845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A measure of productivity and innovation in the pharmaceutical industry 2011-2015.
    Harrison R
    Drugs Today (Barc); 2016 Nov; 52(11):627-633. PubMed ID: 28112281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.